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Background: To investigate the expression of chemokine ligand 2 (CCL2), chemokine ligand 18 (CCL18), and
vascular endothelial growth factor (VEGF) in peripheral blood of patients with gastric cancer and their correlation
with presence of malignancy and disease progression.
Methods: Sixty patients with pathological proved gastric cancer were prospectively included into study. The levels
of CCL2, CCL18, and VEGF in peripheral blood were examined by enzyme-linked immunosorbentassay (ELISA).
Peripheral blood from 20 healthy people was examined as control.
Results: The preoperative serum levels of CCL2, CCL18 and VEGF in gastric cancer patients were significantly higher
than that of controls (P <0.001, P <0.001, and P <0.001, respectively). ROC curve analysis showed that with a cut-off
value of ≥1272.8, the VEGF*CCL2 predicted the presence of gastric cancer with 83% sensitivity and 80% specificity.
Preoperative serum CCL2 was significantly correlated to N stage (P =0.040); CCL18 associated with N stage (P =0.002),
and TNM stage (P =0.002); VEGF correlated to T stage (P =0.000), N stage (P =0.015), and TNM stage (P =0.000).
Conclusion: Preoperative serum levels of CCL2 and VEGF could play a crucial role in predicting the presence and
progression of gastric cancer.
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Although the incidence of gastric cancer has been sub-
stantially declining for several decades, it was still the
fourth most common cancer and the second most fre-
quent cause of cancer death [1,2]. The high death rate
was related to the difficulty of detecting gastric cancer at
an early stage. Some serum tumor markers such as AFP,
CEA, CA19-9, CA72-4, and CA50 were currently the
best clinical markers for gastric cancer. However, they
were no good diagnostic tumor makers in early stage
gastric cancer. Therefore, it was important to develop
new markers for detecting gastric cancer.* Correspondence: wangyn1111@hotmail.com
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reproduction in any medium, provided the orChemokines were a kind of low-molecular weight cy-
tokines, which were implicated in many biological pro-
cesses, such as migration of leukocytes, angiogenesis,
and tumor growth. The CCL chemokines represented
the largest family of chemokines. They could attract
monocytes, macrophages, T cells, B cells, eosinophils,
dendritic cells, mast cells and natural killer cells [3].
CCL2 was a 76-amino acid protein that was originally puri-
fied and cloned from human gliomas and myelomonocytic
cells in 1989 [4]. CCL2 was the first chemokine discovered
in the C-C subfamily of chemokines and was produced by
a variety of cells. Some studies have implicated that CCL2
was an active participant in the tumor microenvironment
[5,6]. CCL18 was a newly defined member of C-C sub-
group of chemokines. It played an important role in in-
flammation and generation of the immune response.
However, the involvement of CCL18 in cancer was not
clear.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Comparisons of serum CCL2, CCL18, and VEGF
levels between gastric cancer patients and control
groups
N Mean (pg/ml) Std. deviation P
CCL2 < 0.001
Patients 60 25.05 1.22
Controls 20 15.95 1.15
CCL18 < 0.001
Patients 60 115.94 22.56
Controls 20 42.46 13.97
VEGF < 0.001
Patients 60 132.92 10.50
Controls 20 59.02 6.28
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isolated from the culture supernatant and the ascites of
rodent tumors a potent vascular permeability factor [7].
It was thought to be one of the most important factors
promoting vascularization [8]. It played a role in both
physical and malignant conditions [9]. Previous studies
reported that serum VEGF level was high in several can-
cers, such as breast cancer and colon cancer [10,11].
The aim of this study was to investigate the relation-
ship between the preoperative serum levels of CCL2,
CCL18, and VEGF, and the clinicopathological factors in
patients with gastric cancer.
Methods
Study population
From July 2005 to December 2005, 60 patients who
underwent curative gastrectomy at department of Gas-
tric Cancer and Soft Tissue Sarcoma in Shanghai Cancer
Hospital were included into this study. All patients were
confirmed as gastric cancer by preoperative biopsy. No pa-
tients received neoadjuvant treatment or preoperative
blood transfusion. Additionally, 20 normal persons were
designated as the control. Staging was performed according
to the American Joint Committee on Cancer (AJCC) TNM
Staging Classification for Carcinoma of the Stomach (6th
edition, 2002). Data were retrieved from patients’ operative
and pathological reports. The written informed consent
had been obtained from all the patients, and this study was
approved by the Ethical Committee of Shanghai Cancer
Center of Fudan University.
Blood samples
Blood samples were obtained by peripheral venous
puncture on the day before operation. After clotting and
within an hour of collection, the blood samples were
centrifuged at 3000 g for 5 min and serum aliquots were
stored at -80°C until analysis.
ELISA
The measurement of CCL2, CCL18, and VEGF was
performed using Quantikine human CCL2, CCL18, and
VEGF sandwich enzyme-linked immunosorbent assay
(ELISA) kits (Genzyme Corporation, USA) according to
the manufacturer’s instructions. All assays were duplicated.
Statistical analysis
Continuous variables and categorical variables were
expressed as mean ± 1 standard deviation and percentages,
respectively. The Kolmogorov-Smirnov test was used to
assess whether the continuous variables conformed to a
Gaussian pattern. Comparisons of continuous variables
between independent groups were performed with Stu-
dent’s unpaired t-test or Mann–Whitney non-parametric
test. Comparisons of continuous variables between relatedgroups were performed with Student’s paired t-test and
non-parametric Wilcoxon’s signed-rank test. Linear corre-
lations were assessed by calculating Pearson’s correlation
coefficient or the non-parametric Spearman’s rho. The ac-
cepted level of significance was P <0.05. Statistical analyses
and graphics were performed with the SPSS 13.0 statistical
package (SPSS, Inc., Chicago, IL).
Results
Clinicopathological characteristics
There were 14 males and 6 females (2.33:1) with a mean
age of 56 years in normal persons. There were 41 males
and 19 females (2.16:1) with a mean age of 55 years.
There was 7 (11.7%) early gastric cancers and 53 (88.3%)
advanced gastric cancers. According to histological type,
well-differentiated tumors were observed in 1 (1.7%) pa-
tients, moderately-differentiated in 18 (30.0%) patients,
and poorly-differentiated tumors in remaining 41
(68.3%) patients. Lymph node metastasis was observed
in 40 patients, the metastasis rate was 66.7%. The distri-
bution of pathological stage was as follows: 11 (18.3%)
patients belonged to stage I, 9 (15.1%) II, 23 (38.3%) III,
17 (28.3%) IV.
Serum CCL12, CCL18, and VEGF values
The serum values of CCL2, CCL18, and VEGF in normal
persons were 15.95 ± 1.15 (pg/ml), 42.46 ± 13.97 (pg/ml),
and 59.02 ± 6.28 (pg/ml), respectively. The serum values of
CCL2, CCL18, and VEGF in gastric cancers were 25.05 ±
1.22 (pg/ml), 115.94 ± 22.56 (pg/ml), and 132.92 ± 10.50
(pg/ml), respectively. The levels were significantly higher in
patients than that of control groups (Table 1).
Presence of malignancy
Serum VEGF and CCL2 levels were significant inde-
pendent predictors for the presence of gastric cancer.
The optimal predictive model (χ2 =41.470, df =3, N =80,
Negelkerke R2 =0.599, P <0.001) predicted presence of
Figure 1 Combined ROC curve of serum CCL2 (area under the
curve 0.79, P < 0.001), VEGF (area under the curve 0.83, P < 0.001)
and CCL2*VEGF cut-off values for the presence of gastric cancer.
The ration value was the predictor of gastric cancer with the largest
area under the curve (0.90, P < 0.001).
Table 3 The relation between preoperative serum VEGF,
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With a serum VEGF levels cut-off values ≥ 68.2 pg/ml,
the sensitivity and specificity of VEGF to distinguish
patients from controls were 83% and 60%, respect-
ively. In contrast, with a serum CCL2 levels cut-off
values ≥ 16.6 pg/ml, the sensitivity and specificity of
CCL2 to distinguish patients from controls were 78%
and 60%, respectively.
With a cut-off value of ≥1272.8, the VEGF*CCL2 pre-
dicted the presence of gastric cancer with 83% sensitivity
and 80% specificity (Table 2). The concentrations prod-
uct yielded the largest area under the ROC curve (0.895,
P <0.001) (Figure 1).
Correlation of preoperative serum markers and
clinicopathological features
Preoperative serum CCL2 was significantly correlated
to age (r =0.433, P =0.001) and N stage (r = -0.266,
P =0.040). Preoperative serum CCL18 was significantly
associated with histology type (r = -0.296, P =0.022), N
stage (r = -0.384, P =0.002), and TNM stage (r = -0.386,
P =0.002). Preoperative serum VEGF was significantly corre-
lated to T stage (r =0.598, P =0.000) and N stage (r = 0.312,
P =0.015), and TNM stage (r =0.531, P =0.000). There were
no statistically significant correlation of CCL2, CCL18, and
VEGF to gender, vascular invasion, and nervous invasion
(Table 3).
Discussion
Poor survival of gastric cancer was largely due to late-stage
diagnosis. Late-stage diagnosis can be attributed to the fact
that the disease was relatively “asymptomatic” in its early
stage and nonspecific complaints in its late-stage. There-
fore, it was necessary to find out some markers for early
diagnosis of gastric cancer. Thus, we measured the concen-
tration of CCL2, CCL18, and VEGF in a series of 60 serum
samples from gastric cancer. Additionally, a series of 20
serum samples from healthy people was selected as con-
trols. Moreover, we investigated the relationship betweenTable 2 Cut-off values, sensitivity and specificity of
VEGF*CCL2 for distinguishing gastric cancer patients
from controls








In bold, the reference cut-off value that combines optimal sensitivity and
specificity for clinical use.the levels of these markers and the clinicopathological fac-
tors. To our knowledge, no published studies have simul-
taneously studied the diagnostic value of serum CCL2,
CCL18, and VEGF in gastric cancer patients.
In the current study, we found that the serum levels of
CCL2, CCL18, and VEGF markedly increased in gastric
cancer group compared to control group. It was gener-
ally accepted that CCL2 was a potent proinflammatory
mediator produced by several cells including monocytes
[12]. Additionally, tumor cells or peritumoral compo-
nents can produce cytokines [13]. CCL2 has beenCCL12, CCL18 and clinicopathological parameters in
gastric cancer patients
Parameters VEGF CCL2 CCL18
r P r P r P
T 0.598 0.000 −0.065 0.623 −0.092 0.485
N 0.312 0.015 −0.266 0.040 −0.384 0.002
M 0.166 0.204 0.046 0.724 −0.220 0.091
TNM 0.531 0.000 −0.118 0.370 −0.386 0.002
Histological type −0.115 0.382 0.164 0.211 −0.296 0.022
Venous invasion −0.032 0.807 0.089 0.499 −0.112 0.393
Neuron invasion 0.061 0.644 −0.006 0.962 −0.025 0.848
Gender 0.029 0.826 0.125 0.341 0.088 0.504
Age 0.123 0.348 0.433 0.001 −0.084 0.525
r Correlation coefficients (r).
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breast cancer, ovarian tumor, and gastric cancer [13-15].
Tonouchi et al. [15] reported that the serum concentra-
tion of CCL2 in patients with carcinoma was signifi-
cantly lower than that in controls, which was not
consistent with the current study. In this study, we
found that the serum levels of CCL2 markedly increased
in gastric cancer group compared to control group. The
exact mechanism resulting in this contradiction was not
clear. It was possible that the decreased serum level of
CCL2 may reflect increased local consumption in tumor
[15]. However, others have shown statistically significant
increases in serum CCL2 levels in patients compared
with healthy controls [13,14]. CCL18 played a role in the
homing of T and B cells participating in the immune re-
sponse. It was reported that CCL18 was correlated to
the autoimmune disease. However, the reports about
CC18 in cancer were rare. In this study, we found that
CCL18 markedly increased in gastric cancer group com-
pared to control group. However, it was not independent
predictor for presence of gastric cancer. It was well
known that vascular endothelial growth factor (VEGF)
family played an important role in vasculogenesis and
angiogenesis. Among the VEGF family members, VEGF-
A played an essential role in angiogenesis. However, the
significant value of serum levels of other VEGF members
(VEGF-C and VEGF-d) has been reported [16-18]. How-
ever, previous studies on serum VEGF-C and VEGF-D
in gastric cancer patients have presented with contra-
dictory results. Wang et al. [16] reported that higher
serum levels significantly associated with the presence of
malignancy and lymph node metastasis. To the contrary,
AI-Moundhri et al. [17] did not showed significant dif-
ferences of serum VEGF-C between patients and control
groups, and higher VEGF-D in patients. In review of in-
consistent reports, we conducted logistic regression ana-
lysis, and found that serum VEGF was an independent
predictor of the presence of gastric cancer. Furthermore,
we performed the ROC curve to investigate the predictive
value of gastric cancer, and results showed that VEGF*CCL2
could provide higher accuracy for distinguishing gas-
tric cancer patients from controls than alone VEGF
or CCL.
The correlation of CCL2, CCL18, and VEGF with clin-
icopathological variables has been elucidated in various
tumors. Tonouchi H et al. reported that the concentra-
tion of serum CCL2 in gastric cancer patients decreased
in accordance with disease progression [15]. Zohny SF
et al. reported that serum CCL18 was significantly in-
creased in epithelial ovarian cancer with early stages
compared to those with late stages [19]. In this study, we
found the similar results. It was suggested that the con-
sumption of CCL2 and CCL18 increased and production
decreased in accordance with disease progression.Conclusions
CCL2 played an important role in immune response to
tumor. Together with VEGF, they were useful bio-
markers in predicting gastric cancer.
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